RxDoctor Payments Data

William Costanzo, MD

Cardiovascular Disease · Lawrenceville, NJNPI 1376531517

Payments from drug & device makers

$1,296in general payments, 2019–2025

Across 90 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$188
  • Pfizer$174
  • E.r. Squibb & Sons, L.L.C.$155
  • Amgen$146
  • Merck$115
  • Novartis$99
  • plus $417 from 13 others

What the payments were for

  • Food & beverage$1,26097%
  • Education$363%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,296 in reported general payments places this provider in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$165,688
Medicare patients
1,182
Services billed
3,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban379$447,451
EntrestoSacubitril/Valsartan134$147,585
Repatha SureclickEvolocumab94$114,133
XareltoRivaroxaban83$95,003
FarxigaDapagliflozin Propanediol64$53,988
MultaqDronedarone Hcl19$37,010
Pitavastatin Calcium50$25,510
Icosapent Ethyl43$17,554
BrilintaTicagrelor19$13,557
LivaloPitavastatin Calcium11$12,906
Rosuvastatin Calcium483$9,320
Atorvastatin Calcium598$8,181
VascepaIcosapent Ethyl27$7,867
Ezetimibe337$7,687
Metoprolol Succinate432$6,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$174$447,451379 claims
NovartisEntresto$99$147,585134 claims
Johnson & JohnsonXarelto$188$95,00383 claims
AstraZenecaFarxiga, Brilinta$36$67,54583 claims
Sanofi-aventis U.S. LLCMultaq$53$37,01019 claims
Kowa Pharmaceuticals America, Inc.Livalo$58$12,90611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Lawrenceville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →